Table of Contents
- What is Opelconazole?
- Purpose of the Study
- How Opelconazole is Administered
- Study Design
- Who Can Participate?
- Duration and Phases
- Safety and Efficacy Assessment
What is Opelconazole?
Opelconazole, also known by its research name PC945, is a new medication being studied for the prevention and treatment of pulmonary aspergillosis in lung transplant recipients[1]. Pulmonary aspergillosis is a fungal infection in the lungs caused by a type of mold called Aspergillus. This condition can be particularly dangerous for people who have received lung transplants because their immune systems are weakened by anti-rejection medications.
Purpose of the Study
The main goal of this study is to evaluate how safe and well-tolerated Opelconazole is when used to prevent fungal infections in the lungs of people who have had lung transplants[1]. The researchers want to see if Opelconazole can effectively protect these patients from developing pulmonary aspergillosis, which can be a serious complication after a lung transplant.
How Opelconazole is Administered
Opelconazole is given as a nebulizer suspension[1]. This means that the medication is turned into a fine mist that patients can inhale directly into their lungs. In the study, participants receive 14.8 mg of Opelconazole twice daily for 12 weeks[1]. This method of administration allows the medication to reach the lungs directly, where it’s needed most to fight or prevent fungal infections.
Study Design
The study is designed as an open-label, randomized, active-controlled, parallel-group multi-center study[1]. Here’s what these terms mean:
- Open-label: Both the researchers and the participants know which treatment is being given.
- Randomized: Participants are randomly assigned to either receive Opelconazole or the standard of care treatment.
- Active-controlled: The study compares Opelconazole to the current standard treatment (called the “standard of care”) rather than a placebo.
- Parallel-group: Different groups of participants receive different treatments at the same time.
- Multi-center: The study is conducted at multiple hospitals or clinics.
Who Can Participate?
The study is looking for people who have received either a single or double lung transplant and are due to receive a mold-active antifungal medication[1]. This can be either:
- As de novo prophylaxis: This means using the medication to prevent fungal infections in patients who haven’t had any signs of infection yet.
- As pre-emptive therapy: This is for patients who have Aspergillus in their respiratory tract but don’t show any signs of active fungal disease yet.
Duration and Phases
The study is divided into two parts[1]:
- Prophylaxis or Pre-emptive Therapy Phase: This lasts for 12 weeks. During this time, participants receive either Opelconazole or the standard of care treatment.
- Safety Follow-Up Phase: This phase lasts for 4 weeks after the treatment phase ends. During this time, researchers continue to monitor participants for any delayed side effects or other issues.
Safety and Efficacy Assessment
The primary goal of this study is to assess the safety of Opelconazole. Researchers will be looking at how many participants are able to complete the full 12 weeks of therapy[1]. This helps them understand if the medication is well-tolerated by patients.
While the main focus is on safety, the study also includes some exploratory assessments of how effective Opelconazole is. To reduce bias in these assessments, a Data Review Committee will determine if participants have developed pulmonary fungal disease without knowing which treatment they received[1].
